Latest Breaking News On - நோயாளி சேர்க்கை - Page 1 : comparemela.com
CommerceHealthcare HSF® Patient Enrollment Now Integrated with Epic® MyChart®
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
UBC Partners with Surescripts to Provide In-Workflow Specialty Patient Enrollment to Improve Patient Outcomes
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
FDA Filing expected this Q3 for NASDAQ Company s JW-100 treatment for Eczema
briefingwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from briefingwire.com Daily Mail and Mail on Sunday newspapers.
FDA Calendar • Benzinga
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Jupiter Wellness Advances Clinical Pipeline of CBD-Based Topical Treatments
ACCESSWIRE
Four Indications in Clinical Development
JUPITER, FL / ACCESSWIRE / April 29, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced an update on its clinical pipeline of CBD-based therapeutic topical formulations including JW-100 for the treatment of eczema, JW-200 for skin cancer, JW-300 for burns, and JW-400 for herpes cold sores.
Commenced Patient Enrollment for Skin Cancer: Study Completion Expected Q4 2021
Jupiter s JW-200 is designed to provide action and relief in the treatment of Actinic Keratosis (AK), the most common precancer that forms on skin as a result of exposure to ultraviolet (UV) rays. The objective of this double blinded, placebo-controlled study is to evaluate the efficacy of JW-200 in both the treatment and prevention of disease, with a primary efficacy endpoint of the perc